Investors

Jun 23, 2011

CALGARY, June 23, 2011 /CNW/ - Mr. Don McCaffrey, President and CEO of Resverlogix Corp. (TSX:RVX) is pleased to announce today the addition of Professor H. Bryan Brewer to Resverlogix's Clinical Steering Committee.  Professor Brewer, a cardiologist, is currently the Director of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, Washington Hospital Center, Washington, D.C., USA.  Professor Brewer was the former Chief of the Molecular Disease Branch at the National Institute of Health, Bethesda, MD, USA and is a leader and pioneer in the field of high density lipoprotein (HDL) research.  His seminal observations led to the cloning of the Apolipoprotein A-I (ApoA-I) mRNA and the gene.  The availability of the ApoA-I mRNA and gene enabled clinicians and scientists to understand the role of ApoA-I protein in reverse cholesterol transport (RCT) and atherosclerosis protection. 

"Professor Brewer is one of the most well respected pioneers in the field of HDL biology.  He has extensive industry expertise having served as a consultant to major pharmaceutical companies including Abbott, Lilly, Merck, Pfizer, Roche, Sanofi-Aventis and Schering-Plough.  These skills will enhance the activities of our Clinical Steering Committee which is instrumental in the design and conduct of Resverlogix's human clinical trials relating to its lead compound RVX-208," said Mr. McCaffrey. 

Dr. Jan Johansson, Senior Vice President of Medical Affairs of Resverlogix stated, "Dr. Brewer's joining our Clinical Steering Committee further validates RVX-208's unique position in the critically important atherosclerosis market. Our highly differentiated mechanism in HDL biology, the raising of ApoA-I production and enhancement of RCT biomarkers, is seen by many as the most logical approach to harness the benefits of RCT and provide efficient reduction of atherosclerosis burden from coronary arteries. If our lead drug RVX-208 can facilitate this type of effect in high risk CVD patients in only 26 weeks it will be positioned as a new breakthrough treatment for millions of patients around the world".

The Company has gained valuable insight from the recently completed Phase 2 ASSERT trial. The important knowledge from ASSERT enabled us to identify and target high-risk patients for the next trial of RVX-208 called ASSURE.  The Phase 2b ASSURE trial will target high-risk CVD patients who have low HDL.  The AHA 2010 report states that more than 35 million American adults have low HDL. ASSURE is the first Phase 2b clinical trial lasting 26 weeks to examine a novel small molecule, RVX-208, that enhances ApoA-I production in CVD patients with low HDL.  In ASSURE, intravascular ultrasound (IVUS) will be used to measure changes in coronary atherosclerosis as the primary endpoint, while measures of RCT biomarkers will serve as secondary endpoints.

About RVX-208
RVX-208, a small molecule therapeutic that stimulates endogenous ApoA-I production, is positioned to be one of the emerging drugs that holds most promise in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only orally active small molecule that selectively stimulates ApoA-I production to increase levels of HDL.  The use of this approach will enhance HDL functionality in mediating reverse cholesterol transport (RCT). RCT is a pathway by which cholesterol that has accumulated in atherosclerotic plaques within the arterial wall can be transported to the liver for excretion, thus stabilizing, reducing or preventing atherosclerosis disease conditions.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.